Overexpressing Mfn2, which generally triggers mitochondrial fusion, is associated with decreased tumor development and enhanced survival in preclinical models, underscoring the connection between abnormally fused mitochondria and mitophagy-mediated tumor suppression [117]. Here, MFN2 is linked to neoplasm.